-
ASH 2025 | Live Insights on Next-Generation Immunotherapies
At ASH 2025, Dr. Shannuo Li from the University of Utah, USA shares her perspective on emerging strategies for multi-target immune engagement, exploring the potential of simultaneously targeting BCMA, CD38,…
-
ASH China Voice | Professor Cai Zhen: Multidimensional Exploration and Precision Breakthroughs in Multiple Myeloma — From Mechanistic Insights to Therapeutic Innovation
At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Cai Zhen and Professor He Jingsong from The First Affiliated Hospital, Zhejiang University School of Medicine, had 12 studies accepted, comprehensively showcasing systematic investigations in multiple myeloma ranging from basic research to clinical translation. These studies focused on…
-
ASH China Voice | Professor Du Juan: First-Line BCMA/CD19 Dual-Target FasTCAR-T Redefines Outcomes for Patients with Newly Diagnosed Multiple Myeloma
Multiple myeloma is one of the most common hematologic malignancies, characterized by marked biological heterogeneity and a complex disease course. Achieving deep and durable remission at initial diagnosis is critical for improving long-term outcomes. At the recent Annual Meeting of the American Society of Hematology (ASH), Professor Du Juan’s study was selected for oral presentation,…
-
ASH Voice from China丨Professor Hu Kai: Addressing Clinical Needs and FrontiersMultiple Advances in CAR-T Cell Therapy for Relapsed/Refractory Lymphoma
The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell…
-
Professor Zhisong He: Advances and Unresolved Challenges in the Treatment of Non–Muscle-Invasive Bladder Cancer
UroStream : You presented a keynote lecture entitled “Advances and Challenges in NMIBC Treatment.” Could you first outline the current main treatment paradigms for NMIBC and their limitations? Professor Zhisong…
-
Professor Liqun Zhou: Standardized Development and Future Perspectives of Minimally Invasive Surgery for Urologic Tumors
Editor’s Note: With the rapid advancement of modern medical technology, urologic surgery has undergone a series of transformative changes. From traditional open surgery to minimally invasive approaches, and now to…
-
Precision Integration, Intelligent Leadership — Prof. Ye Dingwei Highlights the 15th Shanghai Urologic Oncology Conference
Precision Integration · Intelligent Leadership The 15th Shanghai Urologic Oncology Academic Conference Continues Its Distinguished Legacy UroStream Q: The Shanghai Urologic Oncology Academic Conference has now reached its 15th edition.…
-
Professor Bo Dai Interprets the 2025 Expert Consensus on Full-Course Prostate Cancer Management | 15th Shanghai Urological Oncology Conference
UroStream: Could you introduce the background, development process, and clinical significance of the Expert Consensus on the Full-Course Management of Prostate Cancer (2025 Edition)? Professor Bo Dai: Work on expert…
Connecting Medical Expertise through Media